New Report Confirms Patients Live Longer With Trimodal Therapy

A recently wrapped up ten year study has concluded that trimodal therapy increases survival rates for mesothelioma patients. The report, published in the Journal of Clinical Oncology, studied 6,645 pleural mesothelioma cases. Trimodal therapy includes surgical intervention followed by chemotherapy and radiationtherapy.

Dr. David Nelson, the lead author of the study and thoracic surgeon stated that “Stratified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival compared with surgery alone, with no significant difference between surgery-based and multimodality therapies.”

The trimodal therapy worked best on those with the epithelioid mesothelioma subtype. For those with epitheloid mesothelioma survival times were increased by an average of nine months. While the trimodal therapy provided the greatest increase to patient survival time, the surgery does not come without risk. Pleural mesothelioma is extremely invasive and carries the potential for serious complications. Approximatley 6% of the patients studied died within one month and 15.5% died within 3 months of the surgical intervention.

The Paul Law Firm advocates for victims of asbestos-related diseases. If you or a loved one is suffering from mesothelioma, call the Paul Law Firm. With over 2.5 billion dollars collected for victims of asbestos exposure, we have the knowledge and the experience to fight for you. We also understand that fighting doesn’t just happen in the courtroom. It also happens in a lab where we are fighting for a cure. Check out the Mesothelioma Research Foundation of America here.

Call us today at 1-855 88 LEGAL (885-3425) or contact us online to discuss your case with one of our experienced mesothelioma lawyers